You are here: Home: BCU 2|2003: Marc L Citron, MD: Select publications

Select publications

Clinical trials of dose-dense chemotherapy

Burtness B et al. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. Cancer J Sci Am 1999;5(4):224- 9. Abstract

Citron M et al. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). Breast Cancer Res Treat 2002; Abstract 15.

Eggemann H et al. Sequential dose-dense epirubicin/paclitaxel (E-T) with G-CSF support compared to standard EC – T (epirubicin/cyclophosphamide followed by paclitaxel) for patients with operable breast cancer and 1-3 positive lymph nodes-first toxicity analysis. Breast Cancer Res Treat 2002; Abstract 646.

Fornier MN et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001;7(12):3934-41. Abstract

Fountzilas G et al. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study. Oncology 1998;55(6):508-12. Abstract

Fountzilas G et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 2001;19(8):2232-9. Abstract

Hudis CA. Dose-dense paclitaxel-containing adjuvant therapy for breast cancer. Oncology (Huntingt) 1998;12(1Suppl1):16-8. Abstract

Hudis C et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17(1):93-100. Abstract

Jackisch C et al. Primary endpoint analysis of the Geparduo-study - Preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin/docetaxel combination in operable breast cancer (T2-3, N0-2,M0). Breast Cancer Res Treat 2002; Abstract 152.

Kuemmel S et al. First follow-up data from interval-shortened dose-intensified adjuvant treatment with epirubicin/paclitaxel followed by CMF versus a standard treatment schedule in high-risk node-positive breast cancer patients (N+ 4 – 9 / > 9). Breast Cancer Res Treat 2002; Abstract 643.

Lalisang RI et al. Dose-dense epirubicin and paclitaxel with G-CSF: A study of decreasing intervals in metastatic breast cancer. Br J Cancer 2000;82(12):1914-9. Abstract

Miller KD et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999 Oct;17(10):3033-7. Abstract

Nistico C et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999 Aug;10(8):937-42. Abstract

Nistico C et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000;59(3):223-9. Abstract

Paciucci PA et al. Neo-adjuvant therapy with dose-dense docetaxel (DTX) plus short-term G-CSF support for locally advanced breast cancer (LABC). Proc ASCO 2002; Abstract 1943.

Razis E et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. Cancer Invest 2001;19(2):137-44. Abstract

Rodriguez CA et al. Dose-dense docetaxel and mitoxantrone as first line chemotherapy for metastatic breast cancer (MBC). Proc ASCO 2002; Abstract 1938.

Sanchez-Rovira P et al. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology (Huntingt) 2001;15(2Suppl3):44-7. Abstract

Sanguineti G et al. Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery. Ann Oncol 2001;12(3):373-8. Abstract

Seidman AD et al. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: Preliminary experience in the treatment of metastatic breast cancer. Semin Oncol 1997;24(5Suppl17):S17-72-S17-76. Abstract Seidman AD et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16(10):3353-61. Abstract

Seidman AD. One-hour paclitaxel via weekly infusion: Dose-density with enhanced therapeutic index. Oncology (Huntingt) 1998;12(1Suppl1):19-22. Abstract

Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: Rationale for the MA.21 study. Oncology (Huntingt) 2001;15(5Suppl7):7-13. Abstract

Untch M et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc ASCO 2002; Abstract 133.

von Minckwitz G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001;19(15):3506-15. Abstract

van Rossum CK et al. Dose intensification of epirubicin and paclitaxel with G-CSF support for patients with metastatic breast cancer: A randomized phase II study of dose-dense and doseescalated chemotherapy. Proc ASCO 2002; Abstract 2040.

Home · Search